Home › Funds › MONARCH CAPITAL MANAGEMENT INC › REGN

MONARCH CAPITAL MANAGEMENT INC position in REGN

REGENERON PHARMACEUTICALS · Health Care

MONARCH CAPITAL MANAGEMENT INC reported holding 3,869 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$2.9M, representing 0.67% of its reported portfolio and ranking #44 among its reported holdings. MONARCH CAPITAL MANAGEMENT INC has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)3.87K sh
Reported value held$2.93M
Portfolio Weight0.67%
First reportedQ3 2023
Last changeAdd
Updated2026-10-21

Last updated: 2026-10-21 · Source: SEC EDGAR Form 13F-HR

How MONARCH CAPITAL MANAGEMENT INC's REGN position evolved

MONARCH CAPITAL MANAGEMENT INC first disclosed a stake in REGN in Q3 2023 at 613 shares (US$504K). The position peaked in Q3 2026 at 3,869 shares, worth US$2.9M. Across 13 filings, MONARCH CAPITAL MANAGEMENT INC increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 3,869 shares valued at US$2.9M — an increase of 53 shares quarter over quarter.. Notable position changes include a 106% increase in Q4 2024 (shares fell 11% over the following quarter), a 32% increase in Q1 2025 (shares fell 17% over the following quarter), a 67% increase in Q2 2025 (shares rose 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 613 $504.48K New
Q4 2023 584 $512.92K Reduce
Q1 2024 584 $562.10K Hold
Q2 2024 564 $592.78K Reduce
Q3 2024 518 $544.54K Reduce
Q4 2024 1.07K $760.06K Add
Q1 2025 1.40K $890.46K Add
Q2 2025 2.35K $1.23M Add
Q3 2025 2.92K $1.64M Add
Q4 2025 3.12K $2.41M Add
Q1 2026 3.21K $2.48M Add
Q2 2026 3.82K $2.38M Add
Q3 2026 3.87K $2.93M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has MONARCH CAPITAL MANAGEMENT INC held REGN?

MONARCH CAPITAL MANAGEMENT INC has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is MONARCH CAPITAL MANAGEMENT INC's current position in REGN?

As of Q3 2026, MONARCH CAPITAL MANAGEMENT INC holds 3.87K shares of REGN (REGENERON PHARMACEUTICALS), valued at $2.93M, representing 0.67% of its reported portfolio and ranking #44.

Has MONARCH CAPITAL MANAGEMENT INC been buying or selling REGN?

In the latest 13F filing (Q3 2026), MONARCH CAPITAL MANAGEMENT INC increased its position in REGN. The position peaked in Q3 2026 at 3.87K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.